Literature DB >> 20182763

Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors.

Koji Matsuo, Dwight D Im, Neil B Rosenshein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182763     DOI: 10.1007/s10147-010-0032-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  4 in total

1.  Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

Authors:  Krishnansu S Tewari; Rita S Mehta; Robert A Burger; Ing-Ru Yu; Ainura S Kyshtoobayeva; Bradley J Monk; Alberto Manetta; Michael L Berman; Philip J Disaia; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2005-09       Impact factor: 5.482

2.  Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.

Authors:  Koji Matsuo; Michele L Eno; Dwight D Im; Neil B Rosenshein
Journal:  Arch Gynecol Obstet       Date:  2009-05-20       Impact factor: 2.344

3.  Extreme drug resistance is common after prior exposure to paclitaxel.

Authors:  John P Geisler; Georgiann C Linnemeier; Amanda J Thomas; Kelly J Manahan
Journal:  Gynecol Oncol       Date:  2007-06-11       Impact factor: 5.482

4.  Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.

Authors:  J N McAlpine; S M Eisenkop; N M Spirtos
Journal:  Gynecol Oncol       Date:  2008-07-15       Impact factor: 5.482

  4 in total
  1 in total

1.  In vitro chemoresponse in metachronous pairs of gyneclologic cancers.

Authors:  Heather J Dalton; James Fiorica; Candace K McClure; Rodney P Rocconi; Fernando O Recio; John L Levocchio; Matthew O Burrell; Bradley J Monk
Journal:  Gynecol Oncol Res Pract       Date:  2014-12-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.